This system also confers additional stability on the baculovirus genome, and gives rise to AAV vectors that achieve higher levels of infectivity — potentially enabling greater therapeutic ...

Presentations will feature insights into optimizing VP1 ratios and the development of a high-yielding scalable Sf9-baculovirus platform for AAV production. Lexeo is developing therapies targeting ...

“We are particularly proud of our exciting preclinical data in amyotrophic lateral sclerosis (ALS), Huntington’s disease, and of our optimized AAV & baculovirus production process for one-time ...

VectorY Therapeutics (VectorY), a biotechnology company developing innovative vectorized antibody therapies for the treatment ...